Literature DB >> 23651024

Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

Orna Levran1, Einat Peles, Matthew Randesi, Xu Shu, Jurg Ott, Pei-Hong Shen, Miriam Adelson, Mary Jeanne Kreek.   

Abstract

AIM: The interindividual variability in the dose required for effective methadone maintenance treatment (MMT) for opioid addiction may be influenced in part by genetic variations in genes encoding pharmacodynamic factors of methadone. This study was conducted to identify some of these variants. MATERIALS &
METHODS: This study focused on 11 genes encoding components of the opioidergic (OPRM1, POMC and ARRB2), the dopaminergic (ANKK1 and DRD2) and the glutamatergic pathways (GRIN1 and GRIN2A), as well as the neurotrophin system (NGFB, BDNF, NTRK1 and NTRK2). The study includes 227 Israeli patients undergoing stable MMT.
RESULTS: Out of the 110 variants analyzed, 12 SNPs (in BDNF, NTRK2, OPRM1, DRD2 and ANKK1) were associated with methadone dose (nominal p < 0.05). Of these SNPs, ANKK1 rs7118900 and DRD2 rs2283265 are known to affect gene expression. Logistic regression of five representative SNPs discriminated between individuals requiring a methadone dose of >120 mg/day and <120 mg/day (p = 0.019), and showed moderate sensitivity and specificity (AUC of 0.63 in receiver operating characteristic analysis).
CONCLUSION: This data should stimulate further research on the potential influence and clinical significance of these variants on MMT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651024      PMCID: PMC3867202          DOI: 10.2217/pgs.13.58

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  96 in total

1.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

2.  Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia.

Authors:  J M Mercader; M Ribasés; M Gratacòs; J R González; M Bayés; R de Cid; A Badía; F Fernández-Aranda; X Estivill
Journal:  Genes Brain Behav       Date:  2007-03-21       Impact factor: 3.449

3.  The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.

Authors:  A L Gorman; K J Elliott; C E Inturrisi
Journal:  Neurosci Lett       Date:  1997-02-14       Impact factor: 3.046

Review 4.  Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.

Authors:  Mary Jeanne Kreek; Gavin Bart; Charles Lilly; K Steven LaForge; David A Nielsen
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

5.  The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.

Authors:  E Garrido; T Palomo; G Ponce; I García-Consuegra; M A Jiménez-Arriero; J Hoenicka
Journal:  Neurotox Res       Date:  2010-09-16       Impact factor: 3.911

6.  Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.

Authors:  Robert A Moyer; Danxin Wang; Audrey C Papp; Ryan M Smith; Linda Duque; Deborah C Mash; Wolfgang Sadee
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

7.  Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans.

Authors:  C Dong; M-L Wong; J Licinio
Journal:  Mol Psychiatry       Date:  2009-10-20       Impact factor: 15.992

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder.

Authors:  Lixiang Liu; Tatiana Foroud; Xiaoling Xuei; Wade Berrettini; William Byerley; William Coryell; Rif El-Mallakh; Elliot S Gershon; John R Kelsoe; William B Lawson; Dean F MacKinnon; Melvin McInnis; Francis J McMahon; Dennis L Murphy; John Rice; William Scheftner; Peter P Zandi; Falk W Lohoff; Alexander B Niculescu; Eric T Meyer; Howard J Edenberg; John I Nurnberger
Journal:  Psychiatr Genet       Date:  2008-12       Impact factor: 2.458

10.  A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder.

Authors:  Eva Real; Mònica Gratacòs; Virginia Soria; Geòrgia Escaramís; Pino Alonso; Cinto Segalàs; Mònica Bayés; Rafael de Cid; José M Menchón; Xavier Estivill
Journal:  Biol Psychiatry       Date:  2009-07-09       Impact factor: 13.382

View more
  18 in total

Review 1.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 2.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 3.  Genetics of opiate addiction.

Authors:  Brian Reed; Eduardo R Butelman; Vadim Yuferov; Matthew Randesi; Mary Jeanne Kreek
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 4.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 5.  Pharmacogenomics of methadone: a narrative review of the literature.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Nicole Horn; Brian R Overholser; Sara K Quinney; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2020-07-24       Impact factor: 2.533

6.  Association of the D-amino acid oxidase gene with methadone dose in heroin dependent patients under methadone maintenance treatment.

Authors:  Tung-Hsia Liu; Hsiao-Hui Tsou; Ren-Hua Chung; Shu Chih Liu; Sheng-Chang Wang; Hsiang-Wei Kuo; Chiu-Ping Fang; Andrew C H Chen; Yu-Li Liu
Journal:  J Hum Genet       Date:  2022-01-04       Impact factor: 3.172

7.  Pharmacogenomics of Opioid Treatment for Pain Management.

Authors:  Sarahbeth Howes; Alexandra R Cloutet; Jaeyeon Kweon; Taylor L Powell; Daniel Raza; Elyse M Cornett; Alan D Kaye
Journal:  Methods Mol Biol       Date:  2022

8.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

9.  Effects of DRD2 splicing-regulatory polymorphism and DRD4 48 bp VNTR on crack cocaine addiction.

Authors:  Anderson R Stolf; Renata B Cupertino; Diana Müller; Breno Sanvicente-Vieira; Tatiana Roman; Eduardo S Vitola; Eugenio H Grevet; Lisia von Diemen; Felix H P Kessler; Rodrigo Grassi-Oliveira; Claiton H D Bau; Diego L Rovaris; Flavio Pechansky; Jaqueline B Schuch
Journal:  J Neural Transm (Vienna)       Date:  2018-10-26       Impact factor: 3.575

10.  Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy.

Authors:  Zalina Zahari; Chee Siong Lee; Muslih Abdulkarim Ibrahim; Nurfadhlina Musa; Mohd Azhar Mohd Yasin; Yeong Yeh Lee; Soo Choon Tan; Nasir Mohamad; Rusli Ismail
Journal:  J Pharm Bioallied Sci       Date:  2020-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.